General Information
Revision date
2010-02-23
Product name
Gemcitabine Powder for Solution for Infusion
Product Synonyms
2′-deoxy-2′,2′-difluorocytidine monohydrochloride (β–isomer); Cytidine, 2"-deoxy-2",2"- difluoro-, monohydrochloride
Manufacturer Name
Hospira, Inc
Icons in SDS
Company Information
company name
Hospira, Inc
Section 2
Teratogenic Effects
and/or carcinogenicity of these materials if workplace exposures are not properly controlled. The actual risk in the workplace is not known. Signs and Symptoms In clinical use, adverse effects have included bone marrow suppression (leukopenia, neutropenia, thrombocytopenia, and anemia), nausea, vomiting, diarrhea or constipation, pain, fever, rash, alopecia, stomatitis, dyspnea, hemorrhage, neurotoxicity (mild paresthesias), elevated liver enzymes, and adverse renal effects (proteinuria and hematuria).
Medical Conditions Generally Aggravated by Exposure
Pre-existing hypersensitivity to gemcitabine hydrochloride; pre-existing skin, eye, bone marrow, blood, nervous system, liver, or kidney ailments; pregnancy. Carcinogen Lists: IARC: Not listed NTP: Not listed OSHA: Not listed 1
